



Dabigatran bei Patienten mit Vorhofflimmern:  
Management bei invasiven Eingriffen 
Zusammenfassung  Chirurgische und andere interven-
tionelle  Eingriffe  erfordern  ein  individuelles  Abwägen 





zu  definieren.  Ziel  der  vorliegenden  Expertenempfeh-
lung ist es, ein optimales perioperatives/interventionel-
les Management für Patienten zu beschreiben, die eine 
Dauertherapie  mit  dem  kürzlich  zugelassenen  oralen 
Thrombininhibitor  Dabigatran  erhalten.  Anhand  ver-
schiedener klinischer Routinesituationen wird das Vor-




zwischen  der  letzten  präoperativen  Gabe  von  Dabiga-
tran und dem geplanten Eingriff sowie einer sorgfältigen 
Blutstillung zu achten.
Schlüsselwörter:  Dabigatran,  Bridging,  Chirurgie,  En-
doskopie, Blutung
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Summary  In any type of invasive surgery, the patient’s 





with  atrial  fibrillation  undergoing  long-term  treatment 
with the thrombin inhibitor dabigatran. As we currently 
have  no  routine  laboratory  test  to  measure  therapeutic 




















surgical  or  invasive  procedures,  and  following  acute 
injury [1]. Systematic investigations demonstrating the 
















and  periinterventional  management  for  patients  with 






















1.    Recommendation  for  the  management  of  acute  or 
elective interventions in accordance with the protocol 
of the RE-LY® study.
















Table 1.  The strength of the expert recommendation is ba-
sed on the classification used to formulate the guidelines of 
the European Society of Cardiology [1]
Class of recommendation
Class 1 Evidence and/or general agreement that a specific medication or 
intervention is beneficial, useful, and effective
Class 2 Nonconcurrent evidence and/or no concurrence that a specific 
medication or intervention is beneficial, useful, and effective
Class 3 Evidence and/or general agreement that a specific medication or 
intervention is not beneficial, useful, or effective. Therefore, the 
medication/measure is not recommended
Level of evidence
Level A Study results from several randomized clinical studies or meta-
analyses
Level B Study results of a randomized clinical study or large nonrando-
mized studies
Level C Consensus opinion of the expert group and/or small studies, 
retrospective studies, register data342    Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
consensus report
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Normalization  of  the  Hemoclot  test  after  discontinua-
tion of dabigatran (e.g., preoperatively) practically rules 
out a significant anticoagulatory effect. In addition to the 
Hemoclot test, Ecarin Clotting Time (ECT) is a sensitive 
test to determine the anticoagulatory effect of dabiga-
tran, but is performed at just a few centers [8].
The  Activated  Clotting  Time  (ACT)  is  the  most  fre-









Tooth extractions or other minor surgical 
procedures
The  Summary  of  Product  Characteristics  provides  no 
recommendations concerning the management of tooth 
Table 2.  A summary of the systematic evaluation reveals 
the following potential changes in routine coagulation para-
meters due to dabigatran. (Adapted from [7])
Parameter (unit) Change (dose dependent)
Prothrombin time (PT) (s) ↑
International normalized ratio (INR) ↑
Partial thromboplastin time (aPTT) (s) ↑↑
Thrombin time (TT) (s) ↑↑↑ (to nondetectability)
Activated clotting time (ACT) (s) ↑↑
Fibrinogen assay (Clauss’ method) (mg/dl) ↓↓
Coagulation factors VIII, IX, XI, XII (%) ↓↓
Coagulation factors II, V, VII, X (%) ↓consensus report
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extractions or minor surgical procedures which permit 















ventional  anticoagulants  (VKA,  heparin)  and  the  low 






































Catheter ablation for atrial fibrillation (isolation  
of the pulmonary vein)
As we have data confirming the safety of ablation of atrial 
fibrillation under VKA (INR 2.0–3.0) [14], the following 


























for  catheter-based  interventions.  Due  to  the  potential 
risk of complications and the possible need for cardiac 





























Endoscopic low-risk interventions  














VKA  suggest  that  these  low-risk  interventions  may  be 
performed under ongoing anticoagulation in the thera-
peutic target range (INR 2.0–3.0) because some studies 














Endoscopic high-risk interventions,  













































Table  3.  Operations  or  interventions  with  a  high  risk  of 
bleeding or a high risk of severe complications in the event 
of bleeding. (Adapted from ACCP guidelines; [8])
Aortocoronary bypass operation
Cardiac valve surgery
Surgery for aneurysm of the aorta
Neurosurgical interventions or neuraxial anesthesia




Urological operations in the prostate gland or bladder
Revision surgery for bleeding or infectionconsensus report





therapy  is  recommended  preoperatively.  Postoperati-
vely, depending on the type of surgery and the patient’s 










The  Summary  of  Product  Characteristics  provi-
des recommendations for the management of surgical 
interventions in patients with atrial fibrillation under-

















mic  cerebrovascular  syndrome  the  clinician  should 




mendation  1C).  According  to  the  international  re-
commendations, therapeutic doses of LMWH should 
be concluded at the latest 24 h before the intervention.
4.    Postoperative  prophylaxis  of  venous  thrombosis 
should be administered in accordance with interna-



































commendation  1C).  A  normal  thrombin  time  (TT) 
might rule out a significant effect of dabigatran but TT 
is often prolonged in clinical routine and especially 
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